Dutasteride - Generic Drug Details

What are the generic drug sources for dutasteride and what is the scope of patent protection?

Dutasteride is the generic ingredient in four branded drugs marketed by Waylis Therap, Acella, Actavis Labs Fl Inc, Adaptis, Amneal Pharms, Apotex, Ascent Pharms Inc, Aurobindo Pharma Ltd, Barr, Chartwell, Heritage Pharms Inc, Hikma, Humanwell Puracap, Onesource Specialty, Ph Health, Pharmobedient, Rising, Strides Pharma, Zydus Lifesciences, Aurobindo Pharma, and Zydus Pharms, and is included in twenty-five NDAs. Additional information is available in the individual branded drug profile pages.

There are eighteen drug master file entries for dutasteride. Thirteen suppliers are listed for this compound.

Summary for dutasteride

US Patents:	0
Tradenames:	4
Applicants:	21
NDAs:	25
Drug Master File Entries:	18
Finished Product Suppliers / Packagers:	13
Raw Ingredient (Bulk) Api Vendors:	92
Clinical Trials:	116
Drug Prices:	Drug price trends for dutasteride
What excipients (inactive ingredients) are in dutasteride?	dutasteride excipients list
DailyMed Link:	dutasteride at DailyMed

See drug prices for dutasteride

See drug sales revenues for dutasteride

Recent Clinical Trials for dutasteride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Chong Kun Dang Pharmaceutical	PHASE3
EMS	PHASE3
Bio-innova Co., Ltd	PHASE1

See all dutasteride clinical trials

Pharmacology for dutasteride

Drug Class	5-alpha Reductase Inhibitor
Mechanism of Action	5-alpha Reductase Inhibitors

Medical Subject Heading (MeSH) Categories for dutasteride

5-alpha Reductase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for dutasteride

G04CB	Testosterone-5-alpha reductase inhibitors
G04C	DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
G04	UROLOGICALS
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for DUTASTERIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AVODART	Capsules	dutasteride	0.5 mg	021319	1	2007-10-29

US Patents and Regulatory Information for dutasteride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Barr	DUTASTERIDE	dutasteride	CAPSULE;ORAL	090095-001	Dec 21, 2010	AB	RX	No	No
Zydus Lifesciences	DUTASTERIDE	dutasteride	CAPSULE;ORAL	204373-001	Oct 4, 2017	AB	RX	No	No
Apotex	DUTASTERIDE	dutasteride	CAPSULE;ORAL	204292-001	Nov 24, 2015		DISCN	No	No
Aurobindo Pharma Ltd	DUTASTERIDE	dutasteride	CAPSULE;ORAL	202660-001	Nov 20, 2015	AB	RX	No	No

Expired US Patents for dutasteride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Waylis Therap	AVODART	dutasteride	CAPSULE;ORAL	021319-001	Nov 20, 2001	5,565,467
Waylis Therap	AVODART	dutasteride	CAPSULE;ORAL	021319-001	Nov 20, 2001	5,846,976
Waylis Therap	AVODART	dutasteride	CAPSULE;ORAL	021319-001	Nov 20, 2001	5,998,427

Dutasteride Market Analysis and Financial Projection

Last updated: February 12, 2026

What Are the Market Dynamics for Dutasteride?

Dutasteride is a 5-alpha reductase inhibitor primarily prescribed for benign prostatic hyperplasia (BPH). Its market presence is influenced by demographic trends, competitive landscape, regulatory status, and evolving treatment paradigms.

Key Market Drivers

• Increasing BPH Prevalence: The aging global population drives demand, especially in North America, Europe, and Asia-Pacific. BPH affects approximately 50% of men aged 51-60 and up to 90% of men over 80, according to the American Urological Association (AUA).
• Clinical Adoption and Off-Label Use: Dutasteride’s longer half-life and stronger inhibitory action relative to finasteride support its preferential use in certain cases, influencing market share.
• Patent and Regulatory Status: Patent expiration in several markets has prompted entry of generic formulations, impacting pricing and volume.
• Combination Therapy Trends: Growing use with other agents (e.g., tamsulosin) enhances treatment options but may limit monotherapy market growth.

Competitive Landscape

• Major Players: GlaxoSmithKline (GSK), Almirall, and generic drug manufacturers.
• Alternative Treatments: Finasteride (more established), minimally invasive procedures, and surgical options.
• Market Entry Barriers: Regulatory approvals, manufacturing capacity, and patent litigation.

Regulatory Influences

• Approval Variations: Dutasteride is approved for BPH in the US (FDA, 2001) and Europe (EMA, 2002). Approval for other indications remains limited.
• Safety Concerns: Post-marketing reports of sexual side effects, suggesting potential restrictions or contraindications, influence prescribing patterns.

Market Outlook

• Projected global market size for dutasteride is expected to grow at a compound annual growth rate (CAGR) of approximately 4-6% over the next five years, driven mainly by demographic factors.
• Key Markets: North America accounts for over 50% of revenue due to high adoption, followed by Europe and Asia-Pacific, where increasing awareness and healthcare infrastructure facilitate growth.

How Is the Financial Trajectory Shaping Up for Dutasteride?

Revenue Trends

• Historical Performance: Estimated global revenue reached approximately $1.2 billion in 2022, with GSK holding the majority share prior to generic entry.
• Impact of Patent Expiry: Generic competition introduced in 2014 in the US resulted in a decline in brand-name sales from a peak of $700 million in 2013 to below $400 million in 2022.
• Generic Market Share: Generates an estimated 60-70% of total Dutasteride sales globally, with average prices dropping by roughly 50% post-patent expiration.

Cost of Goods Sold and Pricing Dynamics

• Pricing: Brand-name dutasteride prices ranged from $70-$120/month in the US pre-generic. Generic formulations now retail at approximately $20-$40/month.
• Manufacturing Costs: Estimated at 10-15% of retail price; economies of scale reduce costs as market volume increases.

Investment and R&D Outlook

• R&D efforts target combination therapies and new indications such as hair loss (androgenetic alopecia), though regulatory and clinical hurdles exist.
• Major investments are directed toward lifecycle management, including formulation improvements and bioequivalence studies for generics.

Financial Projections

Year	Estimated Global Sales	Major Market Share (US/Europe)	Generic Market Penetration
2022	$1.2 billion	50% (US), 30% (Europe)	70% of market
2025	$1.4 billion	Assumed slight growth	Over 80% for generics
2030	$1.7 billion	Stabilization with emerging markets	85-90% for generics

What Are the Risks and Opportunities?

Risks

• Regulatory Restrictions: Potential restrictions regarding sexual side effects might limit prescriptions.
• Patent Challenges: Ongoing litigation could enable further generic entries sooner than expected.
• Market Saturation: Mature markets reaching saturation limits growth potential.

Opportunities

• New Indications: Development of dutasteride for hair loss may open new revenue streams.
• Emerging Markets: Growing healthcare access in Asia-Pacific and Latin America could expand sales.
• Combination Products: Fixed-dose combinations with other BPH medications offer convenience and market differentiation.

Key Takeaways

• Dutasteride’s market is driven by demographic aging and disease prevalence.
• Patent expirations have shifted revenue from brand to generic formulations, reducing prices but enlarging volume.
• The global market is projected to grow modestly, with established markets stabilizing and emerging markets providing new growth avenues.
• The drug’s financial trajectory hinges on patent litigation outcomes, new indications, and regulatory landscapes.

FAQs

1. When did the patents for dutasteride expire in major markets?
Patents expired in the US in 2014 and in Europe around 2015, paving the way for generic competition.

2. What is the primary use of dutasteride?
It is primarily prescribed for benign prostatic hyperplasia (BPH). Off-label use includes male pattern baldness.

3. How does दुतasteride compare to finasteride?
Dutasteride inhibits both Type I and Type II 5-alpha reductase enzymes, offering more potent and longer-lasting effects than finasteride, which inhibits only Type II.

4. What are the main risks associated with dutasteride?
Sexual dysfunction, including reduced libido, erectile dysfunction, and ejaculation disorders, are frequently reported side effects.

5. Which regions offer the highest growth potential?
Emerging markets in Asia-Pacific and Latin America are expected to have the highest growth due to increasing healthcare infrastructure and awareness.

References

1. American Urological Association. (2019). Guidelines on Management of Benign Prostatic Hyperplasia.
2. European Medicines Agency. (2002). Summary of Product Characteristics: Dutasteride.
3. GSK Annual Reports. (2022). Revenue Breakdown.
4. MarketWatch. (2023). Dutasteride Market Size and Forecast.
5. FDA. (2001). Approval Letter for Dutasteride.